Altered Expression of Endothelin,Vascular Endothelial Growth Factor,and Its Receptor in Hepatic Tissue in Endotoxemic Rat

Abstract

Sepsis involves a heterogeneous class of syndromes, and septic shock, a severe form of sepsis, is associated with the development of progressive damage in multiple organs. The present study examined the time-dependent alterations of endothelin-1 (ET-1) and vascular endothelial growth factor (VEGF) levels in liver tissue in a septic rat model. Healthy male Wistar rats aged 15 weeks received 15 mg/kg lipopolysaccharide (LPS) and were sacrificed at different time points (1, 3, 6, and 10 hrs after treatment). Rats that did not receive LPS were considered to be controls. A 28-fold increase in the ET-1 level was observed in liver tissue 10 hrs after LPS administration. VEGF was also altered in hepatic tissue in a time-dependent manner. A gradual increase of VEGF expression in liver tissue after LPS administration was observed. Expression of Flt-1, the vascular permeability receptor of VEGF, was also increased in liver tissue after LPS administration. ET-1 is a potent vasoconstrictor and, therefore, may play a role in the regulation of hepatic perfusion in a sepsis model. On the other hand, VEGF may be involved in capillary leakage in liver tissue after LPS administration. The present findings suggest that there might be a loss of balance between the ET-1 and VEGF levels in the septic liver at different time points, which could contribute to the pathogenesis of acute liver injury in endotoxemia.

Get full access to this article

View all access options for this article.

References

Bone RC. The pathogenesis of sepsis. Ann Intern Med 115:457–469, 1991.

Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581–611, 2004.

van der Flier M, Van Leeuwen HJ, Van Kessel KP, Kimpen JL, Hoepelman AI, Geelen SP. Plasma vascular endothelial growth factor in severe sepsis. Shock 23:35–38, 2005.

Battistini B, Forget MA, Laight D. Potential roles for endothelins in systemic inflammatory response syndrome with a particular relation to cytokines. Shock 5:167–183, 1996.

Pittet J, Morel D, Hemsen A, Gunning K, Lacroix JS, Suter P, Lundberg J. Elevated plasma endothelin-1 concentrations are associated with the severity of illness in patients with sepsis. Ann Surg 213:261–264, 1991.

Weitzberg E, Lundberg JM, Rudehill A. Elevated plasma levels of endothelin in patients with sepsis syndrome. Circ Shock 33:222–227, 1991.

Bauer M, Zhang JX, Bauer I, Clemens MG. Endothelin-1 as a regulator of hepatic microcirculation: sublobular distribution of effects and impact on hepatocellular secretory function. Shock 1:457–465, 1994.

Waydhas C, Nast-Kolb D, Jochum M, Trupka A, Lenk S, Fritz H, Duswald KH, Schweiberer L. Inflammatory mediators, infection, sepsis and multiple organ failure after severe trauma. Arch Surg 127:460–467, 1992.

Shindo T, Kurihara H, Kurihara Y, Morita H, Yazaki Y. Upregulation of endothelin-1 and adrenomedullin gene expression in the mouse endotoxin shock model. J Cardiovasc Pharmacol 31:S541–544, 1998.

10.

Wang JH, Redmond HP, Watson RW, Bouchier-Hayes D. Role of lipopolysaccharide and tumor necrosis factor-α in induction of hepatocyte necrosis. Am J Physiol 269:G297–304, 1995.

11.

Oldner A, Wanecek M, Goiny M, Weitzberg E, Rudehill A, Alving K, Sollevi A. The endothelin receptor antagonist bosentan restores gut oxygen delivery and reverses intestinal mucosal acidosis in porcine endotoxin shock. Gut 42:696–702, 1998.

12.

Wanecek M, Oldner A, Rudehill A, Sollevi A, Alving K, Weitzberg E. Cardiopulmonary dysfunction during porcine endotoxin shock is effectively counteracted by the endothelin receptor antagonist bosentan. Shock 7:364–370, 1997.

13.

Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411, 1988.

14.

Rockey DC, Fouassier L, Chung JJ, Carayon A, Vallee P, Rey C, Housset C. Cellular localization of endothelin-1 and increased production in liver injury in the rat: potential for autocrine and paracrine effects on stellate cells. Hepatology 27:472, 1998.

15.

Pinzani M, Milani S, De Franco R, Grappone C, Caligiuri A, Gentilini A, Tosti-Guerra C, Maggi M, Failli P, Ruocco C, Gentilini P. Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology 110:534–548, 1996.

16.

Okumura S, Takei Y, Kawano S, Nagano K, Masuda E, Goto M, Tsuji S, Michida T, Chen SS, Kashiwagi T. Vasoactive effect of endothelin-1 on rat liver in vivo. Hepatology 19:155–161, 1994.

17.

Warner TD, Allcock GH, Mickley EJ, Corder R, Vane JR. Comparative studies with the endothelin receptor antagonists BQ-123 and PD 142893 indicate at least three endothelin receptors. J Cardiovasc Pharmacol 22:S117–S120, 1993.

18.

Housset C, Rockey DC, Bissell DM. Endothelin receptors in rat liver: lipocytes as a contractile target for endothelin-1. Proc Natl Acad Sci U S A 90:9266–9270, 1993.

19.

Tanikawa K. Hepatic sinusoidal cells and sinusoidal circulation. J Gastroenterol Hepatol 10:S8–S11, 1995.

20.

Oldner A, Wanecek M, Weitzberg E, Sundin P, Sollevi A, Rubio C, Hellstrom PM, Alving K, Rudehill A. Differentiated effects on splanchnic homeostasis by selective and non-selective endothelin receptor antagonism in porcine endotoxaemia. Br J Pharmacol 127: 1793–1804, 1999.

21.

Zhang Y, Oliver JR, Horowitz JD. Endothelin B receptor–mediated vasoconstriction induced by endothelin A receptor antagonist. Cardiovasc Res 39:665–673, 1998.

22.

Ruetten H, Thiemermann C. Effect of selective blockade of endothelin ET_B receptors on the liver dysfunction and injury caused by endotoxemia in the rat. Br J Pharmacol 119:479–486, 1996.

23.

Ruetten H, Thiemermann C, Vane JR. Effects of the endothelin receptor antagonist, SB 209670, on circulatory failure and organ injury in endotoxic shock in the anaesthetized rat. Br J Pharmacol 118:198–204, 1996.

24.

Shi B, Wang X, Yang Z. Vascular endothelial growth factors and liver diseases. Hepatogastroenterology 48:1145–1148, 2001.

25.

Perez-Ruiz M, Ros J, Morales-Ruiz M, Navasa M, Colmenero J, Ruizdel-Arbol L, Cejudo P, Claria J, Rivera F, Arroyo V, Rodes J, Jimenez W. Vascular endothelial growth factor production in peritoneal macrophages of cirrhotic patients: regulation by cytokines and bacterial lipopolysaccharide. Hepatology 29:1057–1063, 1999.

26.

Spinella F, Rosano L, Di Castro V, Natali PG, Bagnato A. Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1α in ovarian carcinoma cells. J Biol Chem 277: 27850–27855, 2002.

27.

LeCouter J, Moritz DR, Li B, Phillips GL, Liang XH, Gerber HP, Hillan KJ, Ferrara N. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 299:890–893, 2003.

28.

Dulak J, Jozkowicz A. Regulation of vascular endothelial growth factor synthesis by nitric oxide: facts and controversies. Antioxid Redox Signal 5:123–132, 2003.

29.

Nathan C. Inducible nitric oxide synthase: what difference does it make? J Clin Invest 100:2417–2423, 1997.

30.

Kilbourn RG, Traber DL, Szabo C. Nitric oxide and shock. Dis Mon 43:277–348, 1997.

31.

Otterbein LE, Zuckerbraun BS, Haga M, Liu F, Song R, Usheva A, Stachulak C, Bodyak N, Smith RN, Csizmadia E. Carbon monoxide suppresses arteriosclerotic lesions associated with chronic graft rejection and with balloon injury. Nat Med 9:183–190, 2003.